Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 50, Issue 5, 2009, Pages 829-830

  Marincevic, Millaray ^a   Tobin, Gerard ^a   Rosenquist, Richard ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; ISOLEUCINE; PHENYLALANINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN IGHV; PROTEIN KINASE B; PROTEIN PIK3CA; THREONINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL FUNCTION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; ENZYME ACTIVATION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TRISOMY 12;

1-PHOSPHATIDYLINOSITOL 3-KINASE; DNA MUTATIONAL ANALYSIS; ENZYME ACTIVATION; FEMALE; GENE FREQUENCY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION;

EID: 68449103578     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902803651     Document Type: Article

References (11)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657.
2. Vanhaesebrock B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;70:535-602.
3. Samules Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
4. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24:1477-1480.
5. Müller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS, Kawamata N, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leukemia Res 2007;31:27-32.
6. Abubaker J, Bavi PP, Al Harbi S, Siraj AK, Al-Dayel F, Uddin S, et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 2007;21:1-3.
7. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, et al. Constitutively activated phosphstidylinositol- 3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: Association with protein kinase Cd. Blood 2002; 100:3741-3748.
8. Michie AM, Nakagawa R. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia. Hematol Oncol 2006;24:134-138.
9. Longo PG, L Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007;21:110-120.
10. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448: 439-444.
11. Mahmoud IS, Sughayer MA, Mohammad HA, Eshtayeh AA, Awidi AS, EL-Khateeb MS, et al. The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br J Cancer 2008;99: 488-490.